This inventor holds 2 USPTO granted patents and 3 published patent applications. Top assignee: Lyell Immunopharma, Inc.. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Scott Edward Boyken: Innovator in Immunotherapy
Introduction
Scott Edward Boyken is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of immunotherapy, particularly through his innovative patents. With a total of 2 patents, Boyken is recognized for his work in developing advanced therapeutic techniques.
Latest Patents
Boyken's latest patents include groundbreaking inventions that enhance the efficacy of chimeric antigen receptor (CAR) therapies. One of his notable patents is focused on ROR1 targeting chimeric antigen receptors. This patent describes polynucleotides encoding a chimeric polypeptide that includes a c-Jun polypeptide, a ROR1-binding protein, and a truncated EGF receptor. The invention also details cells, such as T cells, that express CARs comprising a ROR1-binding protein and overexpress a c-Jun polypeptide. The overexpression of c-Jun in CAR T cells is shown to improve their properties, particularly in reducing or preventing exhaustion. Another significant patent involves recombinant cell surface markers, which relates to EGFR-derived polypeptides containing short juxtamembrane sequences. This patent includes nucleic acids encoding these polypeptides and methods for improving the cell surface expression of truncated EGFR markers.
Career Highlights
Scott Edward Boyken is currently associated with Lyell Immunopharma, Inc., where he continues to push the boundaries of immunotherapy research. His work is instrumental in developing innovative solutions that address critical challenges in cancer treatment.
Collaborations
Boyken collaborates with esteemed colleagues, including Howell Franklin Moffett and Marc J Lajoie. These partnerships enhance the research and development efforts at Lyell Immunopharma, Inc., fostering a collaborative environment that drives innovation.
Conclusion
Scott Edward Boyken is a key figure in the field of immunotherapy, with a focus on developing advanced CAR therapies. His contributions through patents and collaborations are paving the way for new treatment options in cancer care.